文献速递核素与放射性配体治疗肿瘤 PET/CT

166Ho-scout在肝转移瘤166Ho微球放射栓塞前预测价值优于99mTc-MAA

The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-08-09

本研究在53例肝转移瘤患者中比较166Ho-scout与99mTc-MAA对166Ho治疗剂量的预测价值,通过双盲定性评分和定量吸收剂量分析发现,166Ho-scout在病灶吸收剂量预测上一致性更优,正常肝组织预测两者无差异。

要点

  • 166Ho-scout对肝内病灶分布预测的定性一致性优于99mTc-MAA。
  • 166Ho-scout预测病灶吸收剂量的95%一致性界限比99mTc-MAA更窄。
  • 正常肝组织吸收剂量预测两者一致性无显著差异。

核心结论

  • 166Ho-scout对肝内分布预测价值优于99mTc-MAA。

研究设计与样本

  • 在53例肝转移瘤患者中,治疗前分别进行99mTc-MAA和166Ho-scout两种 scout 剂量操作。
  • 定性分析由两名盲法核医学医师对同一患者的99mTc-MAA、166Ho-scout和166Ho治疗剂量SPECT进行5分制一致性评分。
  • 定量分析基于FDG-PET/CT勾画病灶和正常肝VOI并配准至SPECT/CT,比较预测吸收剂量与治疗后实际吸收剂量。

主要发现

  • 定性分析纳入23次操作(71个病灶,22例患者),166Ho-scout中位评分4分优于99mTc-MAA的2.5分(p < 0.001)。
  • 病灶吸收剂量定量分析显示166Ho-scout的95%一致性界限为-90.3至105.3 Gy,窄于99mTc-MAA的-164.1至197.0 Gy。
  • 正常肝吸收剂量一致性界限在99mTc-MAA为-3.6至4.1 Gy,在166Ho-scout为-2.9至5.5 Gy,两者与治疗剂量的一致性无差异。

关键数值与推荐

  • 定性一致性采用5分制评分,166Ho-scout中位4分 vs 99mTc-MAA中位2.5分(p < 0.001)。
  • 病灶吸收剂量95%一致性界限:166Ho-scout -90.3至105.3 Gy,99mTc-MAA -164.1至197.0 Gy。
  • 正常肝吸收剂量95%一致性界限:99mTc-MAA -3.6至4.1 Gy,166Ho-scout -2.9至5.5 Gy。

临床怎么用

  • 在166Ho微球放射栓塞前,可考虑使用166Ho-scout替代99mTc-MAA进行分布预测。
  • 166Ho-scout可能提高病灶吸收剂量预测的准确性,有助于治疗计划制定。

局限性

  • 定量分析仅纳入23次操作(71个病灶,22例患者),样本量有限。
  • 正常肝吸收剂量预测两种scout剂量无差异,可能影响正常肝保护的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As an alternative to technetium-99m-macroaggregated albumin (99mTc-MAA), a scout dose of holmium-166 (166Ho) microspheres can be used prior to 166Ho-radioembolization. The use of identical particles for pre-treatment and treatment procedures may improve the predictive value of pre-treatment analysis of distribution. The aim of this study was to analyze the agreement between 166Ho-scout and 166Ho-therapeutic dose in comparison with the agreement between 99mTc-MAA and 166Ho-therapeutic dose. METHODS: Two separate scout dose procedures were performed (99mTc-MAA and 166Ho-scout) before treatment in 53 patients. First, qualitative assessment was performed by two blinded nuclear medicine physicians who visually rated the agreement between the 99mTc-MAA, 166Ho-scout, and 166Ho-therapeutic dose SPECT-scans (i.e., all performed in the same patient) on a 5-point scale. Second, agreement was measured quantitatively by delineating lesions and normal liver on FDG-PET/CT. These volumes of interest (VOIs) were co-registered to the SPECT/CT images. The predicted absorbed doses (based on 99mTc-MAA and 166Ho-scout) were compared with the actual absorbed dose on post-treatment SPECT. RESULTS: A total of 23 procedures (71 lesions, 22 patients) were included for analysis. In the qualitative analysis, 166Ho-scout was superior with a median score of 4 vs. 2.5 for 99mTc-MAA (p < 0.001). The quantitative analysis showed significantly narrower 95%-limits of agreement for 166Ho-scout in comparison with 99mTc-MAA when evaluating lesion absorbed dose (- 90.3 and 105.3 Gy vs. - 164.1 and 197.0 Gy, respectively). Evaluation of normal liver absorbed dose did not show difference in agreement between both scout doses and 166Ho-therapeutic dose (- 2.9 and 5.5 Gy vs - 3.6 and 4.1 Gy for 99mTc-MAA and 166Ho-scout, respectively). CONCLUSIONS: In this study, 166Ho-scout was shown to have a superior predictive value for intrahepatic distribution in comparison with 99mTc-MAA.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Smits MLJ, Dassen MG, Prince JF, et al. The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2019. PMID: 31399801. doi:10.1007/s00259-019-04460-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。